Intangible Assets

RLYB appears to have limited proprietary asset protection because its value proposition is not anchored by a broad patent estate or platform-level IP that would materially constrain peer substitution.

Compared with larger biotech peers that often defend pricing power through deeper clinical data, broader patent thickets, or approved-product exclusivity, RLYB’s moat from intangibles looks materially weaker.

The available metrics show deeply negative ROIC and ROCE, which is consistent with intangibles that are not yet translating into durable economic returns versus peers.

No evidence in the provided data indicates regulatory or scientific differentiation strong enough to create persistent pricing power over a 5–10 year horizon.

As a result, intangible assets do not currently appear to be a durable peer-relative advantage.

Switching Costs

RLYB does not appear to benefit from meaningful customer switching costs because biotech buyers and partners can generally reallocate capital or trial support to alternative programs with limited lock-in.

Compared with peers that have approved therapies, embedded commercial relationships, or indispensable clinical infrastructure, RLYB’s switching frictions look minimal.

The negative profitability profile suggests the company has not yet built a recurring commercial base that would make replacement costly for customers or partners.

No evidence provided indicates contractual, workflow, or data integration lock-in that would materially reduce churn versus peers.

Switching costs therefore do not currently support durable pricing power or retention.

Network Effects

RLYB does not show evidence of network effects because drug development assets typically do not become more valuable simply from more users in the way platform businesses do.

Compared with peers that may benefit from ecosystem effects across clinicians, payers, or developer communities, RLYB lacks a visible self-reinforcing adoption loop.

The provided metrics do not indicate scale-driven user accumulation, data flywheels, or partner dependence that would compound advantage over time.

Without a commercialized platform or broad external ecosystem, network effects are not a meaningful moat driver here.

This leaves RLYB structurally behind peers with repeat-use or ecosystem-based advantages.

Cost Advantage

RLYB shows no evidence of a structural cost advantage because its TTM ROIC and ROCE are deeply negative rather than indicating superior unit economics.

Compared with larger peers that can spread R&D, manufacturing, and regulatory overhead across multiple assets, RLYB likely faces higher per-program cost intensity.

The extremely low asset turnover suggests capital is not being deployed with the efficiency needed to create a durable cost edge versus peers.

No provided data supports advantaged manufacturing scale, lower trial costs, or superior operating leverage that would persist over 5–10 years.

Accordingly, cost advantage is not a current source of moat durability.

Efficient Scale

RLYB does not appear to operate in a market structure where it controls a scarce, protected niche at sufficient scale to deter entry or sustain peer-relative pricing power.

Compared with established biotech peers that may own approved indications or concentrated specialty markets, RLYB lacks evidence of efficient-scale protection.

The negative returns and weak asset efficiency imply the company has not yet reached a scale point where fixed-cost absorption creates a durable barrier.

No evidence provided suggests that the addressable market is so small or specialized that one or two players can profitably dominate it.

Efficient scale therefore remains weak and does not materially protect margins or retention versus peers.

Overall Score

RLYB’s moat appears weak versus peers because none of the five structural drivers show durable evidence of pricing power, retention, or scale-based protection, and the negative profitability and efficiency metrics reinforce that the company is not yet converting any potential differentiation into lasting economic advantage.